Expression of B-cells markers in tumor cell surfaces (CD20, CD79a, CD10, CD19) in the CD20 negative patients with relapsed or refractory follicular lymphoma at resample time on fresh tumor biopsy. This evidence concerns the gene MME and neoplasm.